Fuzheng Kang’ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial

BACKGROUND: Patients with advanced non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR) gene respond well to the EGFR tyrosine kinase inhibitor (TKI) gefitinib. Chinese herbal medicine (CHM) has been used as a complementary therapy for cancer for deca...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Trials
Main Authors: Yang, Xiao-Bing, Wu, Wan-yin, Long, Shun-qin, Deng, Hong, Pan, Zong-Qi, He, Wen-Feng, Zhou, Yu-Shu, Liao, Gui-Ya, Li, Qiu-Ping, Xiao, Shu-Jing, Cai, Jiao-Zhi
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4396173/
https://ncbi.nlm.nih.gov/pubmed/25873045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-015-0685-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados